# US 2026/0085095 A1 · Aav capsid variants and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085095 A1
- Document ID: US20260085095A1
- Status: Published application
- Kind: A1
- Application number: 18/865,157
- Filed: 2023-06-01
- Published: 2026-03-26
- Earliest claimed: 2022-06-02
- Assignees: Voyager Therapeutics, Inc.
- Applicants: Voyager Therapeutics, Inc.
- Inventors: Mathieu Emmanuel Nonnenmacher; Jing Lin; Hongxing Wang; Jinzhao Hou; Wei Wang; Jiangyu Li
- Web page: https://patentgrep.com/patent/US20260085095A1

## CPC

- C07K 14/005: from viruses
- C12N 15/1093: {General methods of preparing gene libraries, not provided for in other subgroups}
- C12N 15/86: Viral vectors
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- C12N 2750/14151: Methods of production or purification of viral material
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure relates to compositions and methods for the preparation, use, and/or formulation of adeno-associated virus capsid protein variants.

## Claims

### Claim 1

An adeno-associated virus (AAV) capsid variant, comprising an amino acid sequence having the following formula: [N1]-[N2]-[N3] (SEQ ID NO: 4681), wherein [N2] comprises the amino acid sequence of DWHR (SEQ ID NO: 4682) and wherein:
(i) [N1] comprises positions X1, X2, X3, and X4, wherein position X4 is Q, K, E, S, P, R, N, or H; and/or
(ii) [N3] comprises positions X5, X6, and X7, wherein position X5 is I, V, T, M, S, N, L, or F;
wherein the AAV capsid variant comprises the amino acid sequence of positions 203-736 of SEQ ID NO: 981, or an amino acid sequence at least 95% identical to positions 203-736 of SEQ ID NO: 981.

### Claim 2 (depends on 1)

The AAV capsid variant of claim 1, wherein;
(A) [N1] comprises positions X1, X2, X3, and X4, wherein:
(i) position X1 is T, S, R, A, I, C, N, K, L, or Q;
(ii) position X2 is N, T, G, V, S, Y, K, I, H, D, or F;
(iii) position X3 is T, N, K, D, I, S, P, A, Y, E, V, L, M, R, H, Q, or C; and
(iv) position X4 is Q, K, E, S, P, R, N, or H; and/or
(B) [N3] comprises positions X5, X6, and X7, wherein:
(i) position X6 is A, Y, P, N, S, T, G, E, V, W, F, or Q;
(ii) position X7 is Q, G, N, K, H, R, E, L, P, or M; and
(iii) position X5 is I, V, T, M, S, N, L, or F.

### Claim 3 (depends on 1)

The AAV capsid variant of claim 1, wherein:
(i) [N1] comprises TNTQ (SEQ ID NO: 4688), TNTK (SEQ ID NO: 4689), TNNQ (SEQ ID NO: 4690), SNNQ (SEQ ID NO: 4691), TNKQ (SEQ ID NO: 4692), TNNE (SEQ ID NO: 4693), SNKQ (SEQ ID NO: 4694), SNTQ (SEQ ID NO: 4695), TTNQ (SEQ ID NO: 4696), TNDQ (SEQ ID NO: 4697), TTIQ (SEQ ID NO: 4698), RNTQ (SEQ ID NO: 4699), TTKQ (SEQ ID NO: 4700), TTSQ (SEQ ID NO: 4701), TTDQ (SEQ ID NO: 4702), TNPS (SEQ ID NO: 4703), TNKE (SEQ ID NO: 4704), TTTQ (SEQ ID NO: 4705), TGKQ (SEQ ID NO: 4706), TTAQ (SEQ ID NO: 4707), TVKQ (SEQ ID NO: 4708), TNYQ (SEQ ID NO: 4709), TNTP (SEQ ID NO: 4710), STKQ (SEQ ID NO: 4711), TTEQ (SEQ ID NO: 4712), TSKQ (SEQ ID NO: 4713), TNIQ (SEQ ID NO: 4714), TYNQ (SEQ ID NO: 4715), STIQ (SEQ ID NO: 4716), TTVQ (SEQ ID NO: 4717), TGTQ (SEQ ID NO: 4718), TNTR (SEQ ID NO: 4719), TTLQ (SEQ ID NO: 4720), TTMQ (SEQ ID NO: 4721), ANNQ (SEQ ID NO: 4722), SNIQ (SEQ ID NO: 4723), TKNQ (SEQ ID NO: 4724), TYTQ (SEQ ID NO: 4725), TNKS (SEQ ID NO: 4726), SNTE (SEQ ID NO: 4727), TNTE (SEQ ID NO: 4728), TNIE (SEQ ID NO: 4729), TTRQ (SEQ ID NO: 4730), TNSQ (SEQ ID NO: 4731), TYTK (SEQ ID NO: 4732), TTTK (SEQ ID NO: 4733), TNIK (SEQ ID NO: 4734), SNTK (SEQ ID NO: 4735), TNNK (SEQ ID NO: 4736), TNSK (SEQ ID NO: 4737), TSTK (SEQ ID NO: 4738), TITK (SEQ ID NO: 4739), INTK (SEQ ID NO: 4740), TNAK (SEQ ID NO: 4741), TKTK (SEQ ID NO: 4742), STNQ (SEQ ID NO: 4743), ANTK (SEQ ID NO: 4744), RNNQ (SEQ ID NO: 4745), TGNQ (SEQ ID NO: 4746), TSNQ (SEQ ID NO: 4747), THTK (SEQ ID NO: 4748), TDTK (SEQ ID NO: 4749), TNEQ (SEQ ID NO: 4750), CNTQ (SEQ ID NO: 4751), TNPK (SEQ ID NO: 4752), INNQ (SEQ ID NO: 4753), TYTE (SEQ ID NO: 4754), NNNQ (SEQ ID NO: 4755), KNNQ (SEQ ID NO: 4756), TNNR (SEQ ID NO: 4757), LNNQ (SEQ ID NO: 4758), TINQ (SEQ ID NO: 4759), TNHQ (SEQ ID NO: 4760), STTQ (SEQ ID NO: 4761), SNSQ (SEQ ID NO: 4762), STSQ (SEQ ID NO: 4763), TYIQ (SEQ ID NO: 4764), SGTQ (SEQ ID NO: 4765), THNQ (SEQ ID NO: 4766), TITQ (SEQ ID NO: 4767), TSTQ (SEQ ID NO: 4768), TNSN (SEQ ID NO: 4769), TNQQ (SEQ ID NO: 4770), RNIQ (SEQ ID NO: 4771), TNNP (SEQ ID NO: 4772), TITE (SEQ ID NO: 4773), TNTN (SEQ ID NO: 4774), TFSQ (SEQ ID NO: 4775), RNSQ (SEQ ID NO: 4776), INTQ (SEQ ID NO: 4777), RNTE (SEQ ID NO: 4778), TNNH (SEQ ID NO: 4779), TNMQ (SEQ ID NO: 4780), RTTQ (SEQ ID NO: 4781), SNIE (SEQ ID NO: 4782), TNTS (SEQ ID NO: 4783), KNTQ (SEQ ID NO: 4784), TNLQ (SEQ ID NO: 4785), TSMQ (SEQ ID NO: 4786), SYTQ (SEQ ID NO: 4787), TNCQ (SEQ ID NO: 4788), SSTQ (SEQ ID NO: 4789), TVTQ (SEQ ID NO: 4790), or QNTQ (SEQ ID NO: 4791); and/or
(ii) [N3] comprises IAQ, IAG, IYQ, VPQ, IAN, INQ, VNQ, VYQ, VAN, ISG, ISQ, VAQ, ITQ, TAQ, MAQ, SAQ, IGQ, IEQ, IVO, NAQ, LAQ, IAK, IAH, IPQ, IAR, IAE, IAL, IAP, FAQ, VSQ, VTM, ISM, IWQ, IFQ, IQQ, VQQ, IFM, IAM, or ISN.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The AAV capsid variant of claim 1, wherein;
(i) [N1]-[N2] comprises TNTQDWHR (SEQ ID NO: 4898), TNTKDWHR (SEQ ID NO: 4899), TNNQDWHR (SEQ ID NO: 4900), SNNQDWHR (SEQ ID NO: 4901), TNKQDWHR (SEQ ID NO: 4902), TNNEDWHR (SEQ ID NO: 4903), SNKQDWHR (SEQ ID NO: 4904), SNTQDWHR (SEQ ID NO: 4905), TTNQDWHR (SEQ ID NO: 4906), TNDQDWHR (SEQ ID NO: 4907), TTIQDWHR (SEQ ID NO: 4908), RNTQDWHR (SEQ ID NO: 4909), TTKQDWHR (SEQ ID NO: 4910), TTSQDWHR (SEQ ID NO: 4911), TTDQDWHR (SEQ ID NO: 4912), TNPSDWHR (SEQ ID NO: 4913), TNKEDWHR (SEQ ID NO: 4914), TTTQDWHR (SEQ ID NO: 4915), TGKQDWHR (SEQ ID NO: 4916), TTAQDWHR (SEQ ID NO: 4917), TVKQDWHR (SEQ ID NO: 4918), TNYQDWHR (SEQ ID NO: 4919), TNTPDWHR (SEQ ID NO: 4920), STKQDWHR (SEQ ID NO: 4921), TTEQDWHR (SEQ ID NO: 4922), TSKQDWHR (SEQ ID NO: 4923), TNIQDWHR (SEQ ID NO: 4924), TYNQDWHR (SEQ ID NO: 4925), STIQDWHR (SEQ ID NO: 4926), TTVQDWHR (SEQ ID NO: 4927), TGTQDWHR (SEQ ID NO: 4928), TNTRDWHR (SEQ ID NO: 4929), TTLQDWHR (SEQ ID NO: 4930), TTMQDWHR (SEQ ID NO: 4931), ANNQDWHR (SEQ ID NO: 4932), SNIQDWHR (SEQ ID NO: 4933), TKNQDWHR (SEQ ID NO: 4934), TYTQDWHR (SEQ ID NO: 4935), TNKSDWHR (SEQ ID NO: 4936), SNTEDWHR (SEQ ID NO: 4937), TNTEDWHR (SEQ ID NO: 4938), TNIEDWHR (SEQ ID NO: 4939), TTRQDWHR (SEQ ID NO: 4940), TNSQDWHR (SEQ ID NO: 4941), TYTKDWHR (SEQ ID NO: 4942), TTTKDWHR (SEQ ID NO: 4943), TNIKDWHR (SEQ ID NO: 4944), SNTKDWHR (SEQ ID NO: 4945), TNNKDWHR (SEQ ID NO: 4946), TNSKDWHR (SEQ ID NO: 4947), TSTKDWHR (SEQ ID NO: 4948), TITKDWHR (SEQ ID NO: 4949), INTKDWHR (SEQ ID NO: 4950), TNAKDWHR (SEQ ID NO: 4951), TKTKDWHR (SEQ ID NO: 4952), STNQDWHR (SEQ ID NO: 4953), ANTKDWHR (SEQ ID NO: 4954), RNNQDWHR (SEQ ID NO: 4955), TGNQDWHR (SEQ ID NO: 4956), TSNQDWHR (SEQ ID NO: 4957), THTKDWHR (SEQ ID NO: 4958), TDTKDWHR (SEQ ID NO: 4959), TNEQDWHR (SEQ ID NO: 4960), CNTQDWHR (SEQ ID NO: 4961), TNPKDWHR (SEQ ID NO: 4962), INNQDWHR (SEQ ID NO: 4963), TYTEDWHR (SEQ ID NO: 4964), NNNQDWHR (SEQ ID NO: 4965), KNNQDWHR (SEQ ID NO: 4966), TNNRDWHR (SEQ ID NO: 4967), LNNQDWHR (SEQ ID NO: 4968), TINQDWHR (SEQ ID NO: 4969), TNHQDWHR (SEQ ID NO: 4970), STTQDWHR (SEQ ID NO: 4971), SNSQDWHR (SEQ ID NO: 4972), STSQDWHR (SEQ ID NO: 4973), TYIQDWHR (SEQ ID NO: 4974), SGTQDWHR (SEQ ID NO: 4975), THNQDWHR (SEQ ID NO: 4976), TITQDWHR (SEQ ID NO: 4977), TSTQDWHR (SEQ ID NO: 4978), TNSNDWHR (SEQ ID NO: 4979), TNQQDWHR (SEQ ID NO: 4980), RNIQDWHR (SEQ ID NO: 4981), TNNPDWHR (SEQ ID NO: 4982), TITEDWHR (SEQ ID NO: 4983), TNTNDWHR (SEQ ID NO: 4984), TFSQDWHR (SEQ ID NO: 4985), RNSQDWHR (SEQ ID NO: 4986), INTQDWHR (SEQ ID NO: 4987), RNTEDWHR (SEQ ID NO: 4988), TNNHDWHR (SEQ ID NO: 4989), TNMQDWHR (SEQ ID NO: 4990), RTTQDWHR (SEQ ID NO: 4991), SNIEDWHR (SEQ ID NO: 4992), TNTSDWHR (SEQ ID NO: 4993), KNTQDWHR (SEQ ID NO: 4994), TNLQDWHR (SEQ ID NO: 4995), TSMQDWHR (SEQ ID NO: 4996), SYTQDWHR (SEQ ID NO: 4997), TNCQDWHR (SEQ ID NO: 4998), SSTQDWHR (SEQ ID NO: 4999), TVTQDWHR (SEQ ID NO: 5000), or QNTQDWHR (SEQ ID NO: 5001);
(ii) [N2]-[N3] comprises DWHRIAQ (SEQ ID NO: 5027), DWHRIAG (SEQ ID NO: 5028), DWHRIYQ (SEQ ID NO: 5029), DWHRVPQ (SEQ ID NO: 5030), DWHRIAN (SEQ ID NO: 5031), DWHRINQ (SEQ ID NO: 5032), DWHRVNQ (SEQ ID NO: 5033), DWHRVYQ (SEQ ID NO: 5034), DWHRVAN (SEQ ID NO: 5035), DWHRISG (SEQ ID NO: 5036), DWHRISQ (SEQ ID NO: 5037), DWHR VAQ (SEQ ID NO: 5038), DWHRITQ (SEQ ID NO: 5039), DWHRTAQ (SEQ ID NO: 5040), DWHRMAQ (SEQ ID NO: 5041), DWHRSAQ (SEQ ID NO: 5042), DWHRIGQ (SEQ ID NO: 5043), DWHRIEQ (SEQ ID NO: 5044), DWHRIVQ (SEQ ID NO: 5045), DWHRNAQ (SEQ ID NO: 5046), DWHRLAQ (SEQ ID NO: 5047), DWHRIAK (SEQ ID NO: 5048), DWHRIAH (SEQ ID NO: 5049), DWHRIPQ (SEQ ID NO: 5050), DWHRIAR (SEQ ID NO: 5051), DWHRIAE (SEQ ID NO: 5052), DWHRIAL (SEQ ID NO: 5053), DWHRIAP (SEQ ID NO: 5054), DWHRFAQ (SEQ ID NO: 5055), DWHRVSQ (SEQ ID NO: 5056), DWHR VTM (SEQ ID NO: 5057), DWHRISM (SEQ ID NO: 5058), DWHRIWQ (SEQ ID NO: 5059), DWHRIFQ (SEQ ID NO: 5060), DWHRIQQ (SEQ ID NO: 5061), DWHRVQQ (SEQ ID NO: 5062), DWHRIFM (SEQ ID NO: 5063), DWHRIAM (SEQ ID NO: 5064), or DWHRISN (SEQ ID NO: 5065); and/or
(iii) [N1]-[N2]-[N3] comprises the amino acid sequence of any one of SEQ ID NOs: 343-538.

### Claim at position 6

-13. (canceled)

### Claim 14 (depends on 1)

The AAV capsid variant of claim 1, which further comprises [N4], wherein [N4] comprises TGWV (SEQ ID NO: 5066), TGWA (SEQ ID NO: 5067), TNWS (SEQ ID NO: 5068), SNWV (SEQ ID NO: 5069), TNWV (SEQ ID NO: 5070), TNWI (SEQ ID NO: 5071), NNWV (SEQ ID NO: 5072), TGWS (SEQ ID NO: 5073), TGWI (SEQ ID NO: 5074), TGWC (SEQ ID NO: 5075), TGWG (SEQ ID NO: 5076), SGWV (SEQ ID NO: 5077), PGWV (SEQ ID NO: 5078), TGSV (SEQ ID NO: 5079), TDWV (SEQ ID NO: 5080), TGCV (SEQ ID NO: 5081), TGRV (SEQ ID NO: 5082), TGLV (SEQ ID NO: 5083), TGGV (SEQ ID NO: 5084), AGWV (SEQ ID NO: 5085), IGWV (SEQ ID NO: 5086), TGWD (SEQ ID NO: 5087), NGWV (SEQ ID NO: 5088), TGWF (SEQ ID NO: 5089), TRWV (SEQ ID NO: 5090), TVWV (SEQ ID NO: 5091), TGWL (SEQ ID NO: 5092), TAWV (SEQ ID NO: 5093), TSWV (SEQ ID NO: 5094), TGWT (SEQ ID NO: 5095), SVWV (SEQ ID NO: 5096), TQWV (SEQ ID NO: 5097), or PGWG (SEQ ID NO: 5098).

### Claim 15 (depends on 14)

The AAV capsid variant of claim 14, wherein [N1]-[N2]-[N3]-[N4] comprises:
(i) the amino acid sequence of any one of SEQ ID NOs: 201-245, 247-250, 253-255, 257-265, 268-274, 276-286, 288, 290-297, 299-303, 305-309, 311, 313-319, 323-328, 330-337, 339-342, 539-542, 544, 546, 547, 549-557, 559-589, 592, 593, 595, 596, 598, 599, 601-608, 610-614, 616-622, 625, 628, 630, 631, 633, 636, 638, 639-646, 649, 651-657, 667, 669, 670, 672, 673, 679-683, 685-690, 692, 693, 695, 697, 699-701, 703-705, 708-710, 712-717, 719-723, 728-731, 733-738, 740, or 742;
(ii)
(SEQ ID NO: 201)
TNTQDWHRIAQTGWV;
or
(iii)
(SEQ ID NO: 202)
TNTKDWHRIAQTGWV.

### Claim 16

(canceled)

### Claim 17 (depends on 14)

The AAV capsid variant of claim 14, wherein:
(i) [N1]-[N2]-[N3] is present in loop VIII, wherein loop VIII comprises positions 580-599 of SEQ ID NO: 981;
(ii) [N4] is present in loop VIII, wherein loop VIII comprises positions 580-599 of SEQ ID NO: 981;
(iii) X1 of [N1] is present at position 582, X2 of [N1] is present at position 583, X3 of [N1] is present at position 584, and X4 of [N1] is present at position 585, numbered according to SEQ ID NO: 981;
(iv) [N2] is present at positions 586-589, numbered according to SEQ ID NO: 981;
(v) X5 of [N3] is present at position 590, X6 of [N3] is present at position 591, and X7 of [N3] is present at position 592, numbered according to SEQ ID NO: 981; and
(vi) [N4] is present at positions 593, 596, numbered according to SEQ ID NO: 981.

### Claim 18

An adeno-associated virus (AAV) capsid variant comprising:
(a) the amino acid sequence of any of the sequences provided in Tables 1, 2A, 2B, 9, 14, 15 or 16;
(b) an amino acid sequence comprising at least 7, 8, 9, 10, 11, 12, 13, or 14 consecutive amino acids from any one of the sequences provided in Tables 1, 2A, 2B, 9, 14, 15, or 16;
(c) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids, relative to any one of the sequences provided in Tables 1, 2A, 2B, 9, 14, 15, or 16; or
(d) an amino acid sequence comprising at least one, two, or three but no more than four substitutions, relative to the amino acid sequence of any one of the sequences provided in Tables 1, 2A, 2B, 9, 14, 15, or 16;
wherein the AAV capsid variant comprises the amino acid sequence of positions 203-736 of SEQ ID NO: 981, or an amino acid sequence at least 95% identical to positions 203-736 of SEQ ID NO: 981.

### Claim 19

(canceled)

### Claim 20

An adeno-associated virus (AAV) capsid variant comprising an amino acid sequence at least 95% identical to positions 203-736 of SEQ ID NO: 981, wherein the AAV capsid variant comprises the amino acid T at position 584, the amino acid D at position 586, the amino acid W at position 587, the amino acid H at position 588, the amino acid R at position 589, and the amino acid I at position 590, numbered according to SEQ ID NO: 981.

### Claim at position 14

-22. (canceled)

### Claim 23 (depends on 20)

The AAV capsid variant of claim 20, which comprises:
(i) the amino acid sequence of positions 203-736 of SEQ ID NO: 981, or an amino acid sequence at least 98% identical thereto;
(ii) the amino acid sequence of positions 138-736 of SEQ ID NO: 981, or an amino acid sequence at least 95% or at least 98% identical thereto; and/or
(iii) the amino acid sequence of SEQ ID NO: 981, or an amino acid sequence at least 95% or at least 98% identical thereto.

### Claim at position 16

-26. (canceled)

### Claim 27 (depends on 20)

The AAV capsid variant of claim 20, which has increased tropism for a brain cell or a brain tissue, relative to the tropism of an AAV capsid protein comprising the amino acid sequence of SEQ ID NO: 138.

### Claim 28 (depends on 20)

A polynucleotide encoding the AAV capsid variant of claim 20, optionally wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 983, or a nucleotide sequence at least 90% identical thereto.

### Claim 29

(canceled)

### Claim 30

A peptide comprising:
(a) the amino acid sequence of any of the sequences provided in Tables 1, 2A, 2B, 14, 15, or 16;
(b) an amino acid sequence comprising at least 7, 8, 9, 10, 11, 12, 13, or 14 consecutive amino acids from any one of the sequences provided in Tables 1, 2A, 2B, 14, 15, or 16;
(c) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids relative to the amino acid sequence of any one of the sequences provided in Tables 1, 2A, 2B, 14, 15, or 16; or
(d) an amino acid sequence comprising at least one, two, or three but no more than four substitutions, relative to the amino acid sequence of any one of the sequences provided in Tables 1, 2A, 2B, 14, 15, or 16.

### Claim at position 21

-32. (canceled)

### Claim 33 (depends on 20)

An AAV particle comprising the AAV capsid variant of claim 20.

### Claim 34

(canceled)

### Claim 35 (depends on 33)

The AAV particle of claim 33, which comprises a nucleotide sequence encoding a payload, wherein the encoded payload comprises a protein; an antibody; an enzyme, or an inhibitory RNA.

### Claim at position 25

-37. (canceled)

### Claim 38 (depends on 35)

The AAV particle of claim 35, which further comprises:
(i) a promoter operably linked to the nucleotide sequence encoding the payload;
(ii) a 5′ inverted terminal repeat (ITR) and/or a 3′ ITR;
(iii) an enhancer;
(iv) an intron region;
(v) an exon region;
(vi) a nucleotide sequence encoding a miR binding site; and/or
(vii) a polyadenylation (polyA) signal sequence.

### Claim at position 27

-42. (canceled)

### Claim 43 (depends on 20)

A vector comprising a polynucleotide encoding the AAV capsid variant of claim 20.

### Claim 44 (depends on 20)

A cell comprising the AAV capsid variant of claim 20, optionally wherein:
(i) the cell is a mammalian cell or an insect cell;
(ii) the cell is a cell of a brain region or a spinal cord region; and/or
(iii) the cell is a neuron, a sensory neuron, a motor neuron, an astrocyte, a glial cell, oligodendrocyte, a heart cell, or a muscle cell.

### Claim 45 (depends on 20)

A method of making an AAV particle, comprising:
(i) providing a host cell comprising a viral genome and a polynucleotide encoding the AAV capsid variant of claim 20; and
(ii) incubating the host cell under conditions suitable to enclose the viral genome in the AAV capsid variant;
thereby making the AAV particle.

### Claim 46 (depends on 20)

A pharmaceutical composition comprising, an AAV particle comprising the AAV capsid variant of claim 20, and a pharmaceutically acceptable excipient.

### Claim 47 (depends on 20)

A method of delivering a payload to a cell or tissue comprising administering an AAV particle comprising the AAV capsid variant of claim 20, thereby delivering the payload to the cell or tissue.

### Claim 48 (depends on 47)

The method of claim 47, wherein the cell is:
(i) a cell of a brain region or a spinal cord region;
(ii) a cell of the heart;
(iii) cell of the muscle or liver;
(iv) a neuron, a sensory neuron, a motor neuron, an astrocyte, a glial cell, or an oligodendrocyte; or
(v) in a subject, optionally wherein the subject has, has been diagnosed with having, or is at risk of having a genetic disorder, a neurological disorder, a neuro-oncological disorder, a muscular disorder, or a neuromuscular disorder.

### Claim 49

(canceled)

### Claim 50 (depends on 20)

A method of treating a subject having or diagnosed with having a genetic disorder, a neurological disorder, a neurodegenerative disorder, a neuro-oncological disorder, a muscular disorder, or a neuromuscular disorder, comprising administering to the subject an AAV particle comprising the AAV capsid variant of claim 20, thereby treating the subject.

### Claim at position 36

-61. (canceled)
